CSF1R and neoplasm: Indeed, these observations are in part supported by preclinical studies showing a significant impact of the timing of initiation of anti-CSF-1R therapies, showing diminished anti-tumor activity when CSF-1R inhibitors are administered in mice bearing established tumors versus when therapy is started concurrent with tumor implantation [80].